Early Detection of Amyloidosis in People with Monoclonal Gammopathy
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This trial uses special imaging scans to detect amyloidosis (abnormal protein buildup) early in people who have monoclonal gammopathy (an abnormal blood protein). The goal is to find amyloidosis before it causes serious organ damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be enrolled in the COSMO-AL study (a related research study)
- You must have had a biopsy test done and those results must be available
- You must be able and willing to give written informed consent
- You cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
This early-stage trial tests a new drug called anselamimab for AL amyloidoma—a rare condition where abnormal protein deposits form tumors in one part of your body. The study aims to see if this drug can help shrink or control these deposits in patients who have a visible, removable tumor.
This research study looks at how certain sugar molecules (N-glycosylation) on proteins may play a role in a disease called AL amyloidosis. Researchers will study blood samples from people with related plasma cell disorders to learn more about these sugars, which could help with diagnosis and treatment.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
This study collects blood and other samples, along with health information, from people who have—or might have—amyloidosis. It aims to improve understanding of the disease and support future treatments.
Hear when a new Monoclonal Gammopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.